ImmVira's MVR-T3011 IV completes first dosing in Phase I Clinical Trial

By Hope Hill |

Biotechnology platform ImmVira has reportedly announced that it has commenced MVR-T3011 IV – its lead oncolytic virus therapy program. The first patient as a part of this therapy program has already been dosed, having received MVR-T3011 intravenously in the U.S.

Globally reputed clinical institutions such as Prisma Health, Sarah Cannon Research Institute, and Mary Crowley Cancer Research have been hosting the Phase I clinical trial, claim sources.

For the uninitiated, ImmVira is a biotechnology company that solely focuses on genetically modified oncolytic viruses as cancer therapeutics. The company has worked on developing science, technology, and related know-how in order to support ongoing research and development programs and commercialization of oncolytic viruses on the OV+ Potent, Enabling, Novel & Safe (OvPENS) platform.

The OvPENS platform basically consists of gene-recombinant know-how, patents, research, commercialization analytics, and manufacturing technology to come up with next-generation oncolytic viruses that are enabling, novel, potent, and safe and which hit drug development targets.

Dr. Joy Zhu, Chief Medical Officer (CMO), ImmVira, has been quoted to state that the official entry of MVR-T3011 IV into clinical studies is a major milestone in the oncolytic herpes simplex virus administration. The company is quite hopeful regarding the potential of MVR-T3011 IV to demonstrate a good safety profile and deliver highly promising clinical results, she says, adding that the proper delivery of MVR-T3011 IV is likely to provide a major opportunity to treat numerous advanced cancers which cannot be treated with regular intratumoral injections.

Dr. Grace Zhou, Chief Executive Officer (CEO), ImmVira has reportedly stated that the firm is rather thrilled about the prospects of intravenously administering MVR-T3011 IV. Post the approval of the MVR-T3011 IV's National Medical Products Administration (NMPA) clinical trial in China, the completion of initial dosage in the U.S. thus marks a major step ahead for the company’s pipeline development, she says.

Elaborating further, Dr. Grace Zhou added that ImmVira sees itself revolutionizing the future of oncolytic virotherapy and bringing hope to numerous cancer patients, their caregivers, and families, by leveraging the OvPENS R&D platform that aims at next-gen cancer therapy evolution.



Source Credits:

https://finance.yahoo.com/news/immviras-mvr-t3011-iv-completed-024500177.html

Comments

Post a Comment

Add your comment here

Popular posts

UK PM and Bill Gates announce new green partnership

By Hope Hill |
U.S. business magnate Bill Gates and UK Prime Minister Boris Johnson have made it to the headlines for announcing a new partnership between the government and the Breakthrough Energy Catalyst. The deal entails a substantial amount to be invested in next-gen clean energy technologies. For the unversed, Catalyst is a vital program within the Breakthrough Energy network and brings together a variety of parties – businesspersons, philanthropists, and governments, to invest in climate technologies. Catalyst focuses on four major green technology areas including long term energy storage, direct air capture, green hydrogen, and sustainable aviation fuels. As per sources, the UK government has already pledged to commit GBP 200 million to develop UK projects in these four areas as a part of the GBP 1 billion Net Zero Innovation Portfolio. Businesses that have had tie-ups with the Breakthrough Energy Catalyst will match fund GBP 200 million of that investment to help market these technologies...
Read more

Mars embarks on new initiative to reduce GHG emissions across value chain

By Patrick Miller |
Mars, Incorporated, has declared that it has a new mission in mind. The company has strengthened its commitment to accomplish a state of net zero GHG emissions spanning its overall value chain, by the year 2050. Mars’ mission aligns with the prestigious Paris Agreement, one of the most ambitious climate change action plans, that aims to limit global temperature rises up until 1.5 °C. Grant F. Reid, Chief Executive Officer, Mars, has some real-time insights into the present climate change situation. He has been quoted to state that faster initiatives must be taken at this point of time, since climate change is already well on its way to affecting people and to eliminate this threat, net zero targets must be implemented seamlessly, across whole distribution networks and the results must be depicted soon enough, instead of having to waiting for ages. Reid acknowledges the fact that a lot of loopholes exist in some net zero commitments that reduce their credibility and at large, the cli...
Read more

Munters signs turnkey project to build lithium battery laboratory

By Patrick Miller |
Energy and climate solutions leader Munters has reportedly signed a turnkey project agreement entailing the construction of a laboratory in Scandinavia. As per sources, the company plans to design and build a lithium battery laboratory in the Scandinavian region, strengthening its position as a major supplier to lithium battery producers. Munters’ step ahead may be an action initiated in favor of climate change that is increasing the demand for lithium batteries the world over. Munters’ ability to build the unit and its competence to ensure appropriate execution of the construction was a major requirement by the client. As per terms and conditions, the company will deliver the project over the forthcoming six months. The project valuation adds up to around MSEK 83.5. Klas Forsström, President and Chief Executive Officer, Munters, has been quoted to state that with increasing focus being given on minimizing carbon emissions, there’s a strong megatrend of sustainability in the market...
Read more